UNITY clinical trials

TGR-1202 shows promise in CLL and DLBCL

TGR-1202 is a novel PI3K inhibitor currently being tested in the clinical setting for chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). In the following videos and presentation, the trial chairs provide insight into its novel mechanism of action and potential in the clinical setting.

The content is sponsored by TG Therapeutics.